샘플 요청 목록

 카트 문의
시장보고서
상품코드
1731851

안과용 약물전달 시장

Ocular Drug Delivery
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 489 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

안과용 약물전달 세계 시장은 2030년까지 943억 달러에 이를 전망

2024년에 731억 달러로 추정되는 안과용 약물전달 세계 시장은 2024-2030년 CAGR 4.3%로 성장하여 2030년에는 943억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 국소 기술은 CAGR 5.8%를 나타내고, 분석 기간 종료시에는 352억 달러에 이를 것으로 예측됩니다. 안구 삽입 기술 부문의 성장률은 분석 기간중 CAGR 3.2%로 추정됩니다.

미국 시장은 추정 199억 달러, 중국은 CAGR 8.2%로 성장 예측

미국의 안과용 약물전달 시장은 2024년에 199억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 197억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 8.2%로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.7%와 3.4%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 2.5%를 보일 전망입니다.

세계의 안과용 약물전달 시장 - 주요 동향과 성장 촉진요인 정리

약물 전달이 시력장애 치료의 패러다임을 바꿀 수 있는 이유는 무엇일까?

약물 전달은 안과 영역에서 빠르게 발전하고 있는 분야로, 해부학적 장벽을 극복하고 치료 농도의 지속성을 유지하면서 안구 내 표적 조직에 치료제를 직접 전달해야 할 필요성에 힘입어 빠르게 발전하고 있습니다. 각막, 혈액-방수 장벽, 혈액-망막 장벽과 같은 보호 장벽을 포함하는 안구의 독특한 구조로 인해 기존의 전신 또는 국소 약물 전달은 후안부 질환의 치료에 거의 효과가 없습니다. 따라서 국소화, 표적화, 서방형 약물 전달 플랫폼에 대한 기술 혁신이 필요합니다.

노화성 황반변성(AMD), 당뇨망막병증, 녹내장, 포도막염과 같은 안질환이 전 세계적으로 증가함에 따라, 효과적이고 환자 맞춤형 전달 시스템에 대한 수요가 증가하고 있습니다. 점안제나 유리체강 내 주사와 같은 전통적인 투여 경로는 낮은 생체 이용률, 짧은 작용 시간, 환자의 복약 순응도 문제로 인해 한계에 부딪히고 있습니다. 임플란트, 나노 캐리어, in situ 형성 젤, 마이크로니들 어레이와 같은 신기술은 약물의 침투성을 높이고, 방출 프로파일을 확장하고, 침습성을 최소화함으로써 이러한 한계에 대응하고 있습니다. 인구 고령화와 당뇨병 유병률 증가로 시력을 위협하는 질병이 점점 더 널리 퍼지고 있는 가운데, 약물 전달은 안과 의료의 중요한 축이 되고 있습니다.

약물 전달의 혁신이 안과에서 유효성, 안전성, 환자 순응도를 어떻게 향상시키고 있는가?

최첨단 약물 전달 플랫폼은 생분해성 임플란트(덱사메타손 유리체내 임플란트 등), 재충전 가능한 저장소, 나노입자 기반 캐리어 등 다양한 기술을 통해 더 긴 치료 기간과 조직 특이성을 제공합니다. 이러한 시스템은 몇 주에서 몇 달에 걸쳐 약물을 방출하고 유리체강 내 주사의 빈도를 줄임으로써 환자의 순응도와 임상 결과를 개선합니다. 서방형 코르티코스테로이드와 항VEGF제는 현재 만성 망막 질환의 관리에 있어 더 적은 횟수의 개입으로 일상적으로 사용되고 있습니다.

국소 나노미셀, 리포좀, 덴드리머, 하이드로겔은 주사없이 전안부나 후안부에 투여할 수 있도록 개발되고 있습니다. 온도, pH, 효소 트리거에 반응하는 in situ 형성 젤과 안구 삽입물은 약물의 체류시간과 치료 반응을 개선하고 있습니다. 약물 방출을 제어할 수 있는 이식형 마이크로펌프와 전자 장치도 개발 중으로, 디지털 치료와 약물 전달의 융합을 상징합니다. 이러한 기술들은 안과 치료제의 약동학적, 약력학적 상황을 재정의하고, 정확하고 프로그램 가능한 환자 친화적인 치료 패러다임을 가능하게 하고 있습니다.

첨단 안구 전달 솔루션에 대한 수요를 주도하는 임상 적응증과 지역 의료 시스템은 무엇인가?

AMD, 당뇨황반부종(DME), 망막정맥폐쇄증과 같은 만성 후안부 질환은 유리체내 안과용 약물전달시스템 및 서방형 안과용 약물전달시스템에 대한 수요를 견인하는 가장 큰 요인입니다. 녹내장 치료 역시 약물 순응도 및 안압 조절을 개선하기 위해 이식형 장치 및 방출 제어 메커니즘으로 전환하고 있습니다. 소아 안과와 노인 안과는 약물 전달과 순응도 문제가 특히 심각한 성장 분야로, 1일 1회 투여 제형과 디포짓 제형의 필요성이 강조되고 있습니다.

북미와 유럽은 약사 승인, 시판 제품 가용성, 안과 전문 의료 인프라 측면에서 선두를 달리고 있습니다. 미국 시장에서는 FDA 승인 임플란트 및 나노 제제의 급속한 보급이 이루어지고 있으며, 유럽 시장은 집중적인 상환과 높은 미충족 수요의 혜택을 누리고 있습니다. 아시아태평양은 인구 고령화, 당뇨병 인구 증가, 정부 주도의 실명 예방 이니셔티브에 힘입어 일본, 인도, 중국을 중심으로 높은 수요 증가를 보이고 있습니다. 라틴아메리카와 중동은 민관 파트너십과 안과 의료 NGO 프로그램을 통해 첨단 약물 전달 플랫폼을 점점 더 많이 도입하고 있으며, 안과 의료 NGO 프로그램을 통해 접근성을 확대하고 있습니다.

약물 전달 시장의 장기적인 성장과 분야별 혁신의 원동력은 무엇인가?

약물 전달 시장 성장의 원동력은 시력 손실의 유병률 증가, 치료 부담 경감의 필요성, 제약 공학, 바이오 소재 및 나노기술의 발전입니다. 제약회사들이 환자 중심의 혁신을 통해 안과 포트폴리오를 차별화하기 위해 경쟁하는 가운데, 의약품 개발자, 기기 제조업체, 재료 과학자들의 협업으로 획기적인 치료법이 탄생하고 있습니다. 바이오시밀러, 유전자치료제, 병용투여 플랫폼은 부작용을 최소화하면서 안과적 생체 이용률을 최적화하는 약물 전달 시스템과 통합되고 있습니다.

약물 전달을 보완하고 치료 반응을 추적하기 위해 인공지능, 원격 모니터링, 스마트 안과 기기들이 연구되고 있습니다. 희귀 안과용 의약품에 대한 규제 혜택과 혁신적인 전달 플랫폼에 대한 패스트트랙 지정으로 시장 진입이 가속화되고 있습니다. 의약품, 생물학적 제제, 디바이스의 경계가 모호해짐에 따라 약물 전달은 안과에서 정밀 의학의 초점이 되고 있습니다.

부문

기술(외용제, 안내 삽입제, 안내 임플란트, 안내 겔, 기타 기술), 제제 유형(연고, 용액, 유제, 현탁액, 기타 제제 유형), 적응 질환(녹내장, 당뇨병 망막증, 안구건조증, 노인황반변성, 기타 적응 질환), 최종사용자(병원, 안과 클리닉, 기타 최종사용자)

조사 대상 기업 예(주목 합계 42개사)

  • AbbVie Inc.
  • Aciont Inc.
  • Alcon
  • Alimera Sciences, Inc.
  • Allergan(an AbbVie company)
  • Bausch Health Companies Inc.
  • Clearside Biomedical, Inc.
  • EyeGate Pharmaceuticals, Inc.
  • Eyenovia, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • Genentech, Inc.
  • Graybug Vision, Inc.
  • Iris Pharma
  • Johnson & Johnson Vision Care, Inc.
  • Kiora Pharmaceuticals, Inc.
  • Nicox S.A.
  • Novaliq GmbH
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • Oculis SA

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수익원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

무료 업데이트 각국의 최종 리셋이 발표된 후, 7월에 무료 업데이트 버전을 고객님들께 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <>& 중국 <>& 멕시코 <>& 캐나다 <>&EU <>& 일본 <>& 인도 <>& 기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.06.05

Global Ocular Drug Delivery Market to Reach US$94.3 Billion by 2030

The global market for Ocular Drug Delivery estimated at US$73.1 Billion in the year 2024, is expected to reach US$94.3 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Topical Technology, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$35.2 Billion by the end of the analysis period. Growth in the Ocular Insert Technology segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$19.9 Billion While China is Forecast to Grow at 8.2% CAGR

The Ocular Drug Delivery market in the U.S. is estimated at US$19.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$19.7 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Ocular Drug Delivery Market - Key Trends & Drivers Summarized

Why Is Ocular Drug Delivery Undergoing a Paradigm Shift in Treating Vision-Threatening Disorders?

Ocular drug delivery is a rapidly evolving domain in ophthalmology, driven by the need to deliver therapeutic agents directly to target tissues within the eye while overcoming anatomical barriers and maintaining sustained therapeutic concentrations. The unique structure of the eye-including protective barriers like the cornea, blood-aqueous barrier, and blood-retinal barrier-makes conventional systemic or topical drug delivery largely ineffective for treating posterior segment diseases. This has necessitated innovation in localized, targeted, and extended-release drug delivery platforms.

The rising global burden of ocular diseases such as age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and uveitis is creating unprecedented demand for effective and patient-compliant delivery systems. Traditional routes such as eye drops and intravitreal injections are limited by poor bioavailability, short duration of action, and patient adherence issues. Emerging technologies, including implants, nano-carriers, in situ forming gels, and microneedle arrays, are addressing these limitations by enhancing drug penetration, extending release profiles, and minimizing invasiveness. As sight-threatening conditions become more prevalent with aging populations and rising diabetes rates, ocular drug delivery is becoming a critical pillar of ophthalmic care.

How Are Drug Delivery Innovations Improving Efficacy, Safety, and Patient Compliance in Ophthalmology?

Cutting-edge ocular drug delivery platforms are achieving longer therapeutic duration and tissue specificity through a range of technologies, including biodegradable implants (e.g., dexamethasone intravitreal implants), refillable reservoirs, and nanoparticle-based carriers. These systems release drugs over weeks to months, reducing the frequency of intravitreal injections and thereby improving patient compliance and clinical outcomes. Sustained-release corticosteroids and anti-VEGF agents are now routinely used in managing chronic retinal diseases with fewer interventions.

Topical nanomicelles, liposomes, dendrimers, and hydrogels are being developed to enable anterior and posterior segment delivery without the need for injections. In situ-forming gels and ocular inserts that respond to temperature, pH, or enzymatic triggers are improving drug residence time and therapeutic response. Implantable micro-pumps and electronic devices capable of controlled drug release are also in development, representing the convergence of digital therapeutics with pharmaceutical delivery. These technologies are redefining the pharmacokinetic and pharmacodynamic landscape of ocular therapeutics, enabling precise, programmable, and patient-friendly treatment paradigms.

Which Clinical Indications and Regional Healthcare Systems Are Driving Demand for Advanced Ocular Delivery Solutions?

Chronic posterior segment disorders-such as AMD, diabetic macular edema (DME), and retinal vein occlusion-are the largest drivers of demand for intravitreal and sustained-release drug delivery systems. Glaucoma treatment is also shifting toward implantable devices and controlled-release mechanisms to improve adherence and intraocular pressure control. Pediatric and geriatric ophthalmology are additional growth areas where drug delivery challenges and compliance issues are particularly acute, highlighting the need for once-daily or depot formulations.

North America and Europe lead in terms of regulatory approvals, commercial product availability, and specialist ophthalmic care infrastructure. The U.S. market has witnessed rapid adoption of FDA-approved implants and nanoformulations, while the European market benefits from centralized reimbursement and high unmet need. Asia-Pacific is witnessing high demand growth, particularly in Japan, India, and China, due to aging populations, diabetic demographics, and government-led blindness prevention initiatives. Latin America and the Middle East are expanding access through public-private partnerships and eye-care NGO programs that increasingly incorporate advanced drug delivery platforms.

What Is Driving Long-Term Growth and Cross-Disciplinary Innovation in the Ocular Drug Delivery Market?

The growth in the ocular drug delivery market is driven by rising vision loss prevalence, treatment burden reduction imperatives, and advances in pharmaceutical engineering, biomaterials, and nanotechnology. As pharmaceutical companies race to differentiate ophthalmic portfolios through patient-centric innovations, collaboration between drug developers, device manufacturers, and materials scientists is yielding transformative therapies. Biosimilars, gene therapies, and dual-drug platforms are being integrated with delivery systems that optimize ocular bioavailability while minimizing side effects.

Artificial intelligence, remote monitoring, and smart ophthalmic devices are being explored to complement drug delivery and track therapeutic response. Regulatory incentives for orphan ophthalmic drugs and fast-track designations for innovative delivery platforms are accelerating market entry. As the boundaries between pharmaceuticals, biologics, and devices blur, ocular drug delivery is becoming a focal point of precision medicine in ophthalmology-promising sight preservation, procedural simplicity, and life-changing outcomes for millions affected by chronic eye conditions.

SCOPE OF STUDY:

The report analyzes the Ocular Drug Delivery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Topical, Ocular Insert, Intraocular Implants, In-Situ Gel, Other Technologies); Formulation Type (Ointment, Solution, Emulsion, Suspension, Other Formulation Types); Disease Indication (Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration, Other Disease Indications); End-User (Hospitals, Ophthalmic Clinics, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • AbbVie Inc.
  • Aciont Inc.
  • Alcon
  • Alimera Sciences, Inc.
  • Allergan (an AbbVie company)
  • Bausch Health Companies Inc.
  • Clearside Biomedical, Inc.
  • EyeGate Pharmaceuticals, Inc.
  • Eyenovia, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • Genentech, Inc.
  • Graybug Vision, Inc.
  • Iris Pharma
  • Johnson & Johnson Vision Care, Inc.
  • Kiora Pharmaceuticals, Inc.
  • Nicox S.A.
  • Novaliq GmbH
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • Oculis SA

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Ocular Drug Delivery - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rise in Chronic Eye Disorders Such as AMD and Glaucoma Drives Demand for Advanced Drug Delivery Systems
    • Innovation in Sustained-Release Implants Strengthens Business Case for Long-Term Ocular Therapies
    • Growth in Diabetic Retinopathy Incidence Spurs Adoption of Intravitreal Drug Delivery Platforms
    • Surge in Biologic and Biosimilar Launches Expands Pipeline of Ophthalmic Drug Candidates
    • Regulatory Approvals of Minimally Invasive Delivery Devices Propel Market Commercialization
    • Emergence of Nanoformulations and Microparticles Throws the Spotlight on Precision Drug Targeting
    • Increased Investment in Gene Therapy and Ocular mRNA Delivery Enhances Pipeline Innovation
    • Growing Focus on Patient Adherence Drives Development of Depot and Injectable Solutions
    • Integration of Smart Contact Lenses and Wearables Supports Real-Time Drug Delivery Monitoring
    • Advancements in Mucoadhesive and Gel-Based Formulations Expand Topical Treatment Effectiveness
    • Global Expansion of Ophthalmology Clinics in Emerging Markets Sustains Access to Advanced Therapies
    • Rising Use of Biodegradable Polymers Enhances Ocular Implant Acceptance and Biocompatibility
    • Clinical Emphasis on Retinal Disease Management Accelerates Adoption of Posterior Segment Delivery Tools
    • Increased Preference for Office-Based Intravitreal Procedures Enhances Outpatient Market Growth
    • Collaborations Between Pharma and Device Firms Propel Innovation in Combination Products
    • Challenges in Formulating Large-Molecule Drugs for Ocular Use Create R&D Bottlenecks
    • Reimbursement Support for Premium Ophthalmic Devices Strengthens Market Expansion
    • Shortage of Eye Care Professionals in Low-Income Regions Spurs Demand for Self-Administered Delivery Systems
    • Increased Use of Animal Models and AI in Ocular Pharmacokinetics Enhances Preclinical Success
    • Growth in Geriatric Population Globally Sustains Chronic Eye Disease Treatment Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Ocular Drug Delivery Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Ocular Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Ocular Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Ocular Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Ocular Insert by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Ocular Insert by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Ocular Insert by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Intraocular Implants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Intraocular Implants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Intraocular Implants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for In-Situ Gel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for In-Situ Gel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for In-Situ Gel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Formulation Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Formulation Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Formulation Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Ointment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Solution by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Solution by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Solution by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Emulsion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Emulsion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Emulsion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Suspension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Suspension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Suspension by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Glaucoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Diabetic Retinopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Diabetic Retinopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Diabetic Retinopathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Dry Eye Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Dry Eye Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Dry Eye Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Age Related Macular Degeneration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Age Related Macular Degeneration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Age Related Macular Degeneration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Ophthalmic Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Ophthalmic Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: World 15-Year Perspective for Ophthalmic Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 56: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 59: USA Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 65: USA Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: USA 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 68: USA Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: USA Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: USA 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Canada 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 80: Canada Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Canada Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Canada 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • JAPAN
    • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Japan 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Japan 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Japan 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Japan Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Japan 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • CHINA
    • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 95: China Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: China 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 98: China Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: China Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: China 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 101: China Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: China 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 104: China Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: China Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: China 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • EUROPE
    • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Ocular Drug Delivery by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Ocular Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Europe 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Europe 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Europe 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Europe Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Europe 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • FRANCE
    • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 122: France Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: France Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: France 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 125: France Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: France Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: France 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 128: France Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: France Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: France 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 131: France Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: France Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: France 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • GERMANY
    • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 134: Germany Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Germany Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Germany 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 137: Germany Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Germany Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Germany 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 140: Germany Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Germany Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Germany 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 143: Germany Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Germany Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Germany 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 146: Italy Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Italy Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Italy 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 149: Italy Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Italy Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Italy 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 152: Italy Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Italy Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Italy 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 155: Italy Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Italy Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Italy 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 158: UK Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: UK Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: UK 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 161: UK Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: UK Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: UK 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 164: UK Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: UK Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: UK 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 167: UK Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: UK Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: UK 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 170: Spain Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Spain Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Spain 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 173: Spain Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Spain Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Spain 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 176: Spain Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Spain Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Spain 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 179: Spain Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Spain Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Spain 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 182: Russia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Russia Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Russia 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 185: Russia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Russia Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Russia 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 188: Russia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Russia Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Russia 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 191: Russia Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Russia Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Russia 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Europe 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Europe Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Europe 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Europe Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Europe 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Europe Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Europe 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Ocular Drug Delivery by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Asia-Pacific Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Asia-Pacific Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 221: Australia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Australia Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Australia 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 224: Australia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Australia Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Australia 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 227: Australia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Australia Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Australia 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 230: Australia Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Australia Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Australia 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • INDIA
    • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 233: India Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: India Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: India 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 236: India Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: India Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: India 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 239: India Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: India Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: India 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 242: India Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: India Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: India 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: South Korea Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: South Korea 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 248: South Korea Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: South Korea Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: South Korea 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 251: South Korea Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: South Korea Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: South Korea 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 254: South Korea Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: South Korea Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: South Korea 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Asia-Pacific Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Rest of Asia-Pacific Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Rest of Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Rest of Asia-Pacific Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Rest of Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for Ocular Drug Delivery by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Latin America 15-Year Perspective for Ocular Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Latin America Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Latin America 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Latin America Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Latin America 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 278: Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Latin America Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Latin America 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 281: Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Latin America Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Latin America 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Argentina Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Argentina 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 287: Argentina Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Argentina Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Argentina 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 290: Argentina Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Argentina Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Argentina 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 293: Argentina Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Argentina Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Argentina 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 296: Brazil Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Brazil Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Brazil 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 299: Brazil Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Brazil Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Brazil 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 302: Brazil Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Brazil Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Brazil 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 305: Brazil Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Brazil Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Brazil 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 308: Mexico Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Mexico Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Mexico 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 311: Mexico Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Mexico Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Mexico 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 314: Mexico Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Mexico Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Mexico 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 317: Mexico Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Mexico Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Mexico 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Rest of Latin America Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Rest of Latin America 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Rest of Latin America Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Rest of Latin America 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Rest of Latin America Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Rest of Latin America 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Rest of Latin America Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Rest of Latin America 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for Ocular Drug Delivery by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Middle East 15-Year Perspective for Ocular Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 335: Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Middle East Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Middle East 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Middle East Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Middle East 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 341: Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Middle East Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Middle East 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 344: Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Middle East Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Middle East 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 347: Iran Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Iran Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Iran 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 350: Iran Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Iran Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Iran 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 353: Iran Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Iran Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Iran 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 356: Iran Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Iran Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Iran 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 359: Israel Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Israel Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Israel 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 362: Israel Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Israel Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Israel 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 365: Israel Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Israel Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: Israel 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 368: Israel Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Israel Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: Israel 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Saudi Arabia Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: Saudi Arabia 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Saudi Arabia Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: Saudi Arabia 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Saudi Arabia Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: Saudi Arabia 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Saudi Arabia Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: Saudi Arabia 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 383: UAE Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: UAE Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: UAE 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 386: UAE Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: UAE Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: UAE 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 389: UAE Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: UAE Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: UAE 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 392: UAE Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: UAE Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: UAE 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Rest of Middle East Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Rest of Middle East 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Rest of Middle East Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: Rest of Middle East 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Rest of Middle East Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 403: Rest of Middle East 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Rest of Middle East Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 406: Rest of Middle East 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
  • AFRICA
    • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 407: Africa Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Africa Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 409: Africa 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 410: Africa Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Africa Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 412: Africa 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
    • TABLE 413: Africa Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Africa Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 415: Africa 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 416: Africa Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Africa Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 418: Africa 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제